Key result
OPTIMAX stent shows a 6.3% MACE rate and no definite stent thrombosis at one year.
Why the study?
The 12-month clinical outcome of the titanium-nitride-oxide-coated OPTIMAX stent in de novo coronary lesions was not well established beyond initial 6-month results.
Does titanium-nitride-oxide-coated cobalt-chromium stent implantation provide safe and effective clinical outcomes in symptomatic patients with de novo coronary lesions?
Observational (n=224)
Does titanium-nitride-oxide-coated cobalt-chromium stent implantation provide safe and effective clinical outcomes in symptomatic patients with de novo coronary lesions?
The OPTIMAX titanium-nitride-oxide-coated cobalt-chromium stent demonstrated a low rate of major adverse cardiac events (6.3%) and no stent thrombosis at 12 months in patients with de novo coronary lesions.
12-month real-world data on OPTIMAX stent extend prior 6-month observations; leaves open need for randomized comparisons before practice change.
OBJECTIVES: We explored the 12-month clinical outcome of the titanium-nitride-oxide-coated OPTIMAX stent based on cobalt-chromium platform. BACKGROUND: The OPTIMAX stent demonstrated a satisfactory 6-month clinical outcome in de novo coronary lesions. METHODS: We enrolled 224 consecutive symptomatic patients with significant (50%) stenosis in de novo coronary lesions, who were treated with OPTIMAX stent implantation. The primary endpoint was major adverse cardiac events at 12-month follow-up, defined as a composite of cardiac death, non-fatal myocardial infarction (MI), or ischemia-driven target lesion revascularization (TLR). Stent thrombosis was adjudicated according to the definition of the Academic Research Consortium. RESULTS: The mean age of the cohort was 67 ± 8 years (75% males). Patients presented with acute coronary syndrome in 62.1%. Radial access was used in 92%; complex (type B and C) lesions were treated in 79.9%. Both procedural and clinical success occurred in 100% of the cases. The mean follow-up period was 366 ± 22 days. At 12-month follow-up, the primary endpoint occurred in 14 (6.3%) patients. Cardiac death occurred in three (1.3%) patients, non-fatal MI in seven (3.1%) patients, and ischemia-driven TLR in seven (3.1%) patients. No definite stent thrombosis occurred. CONCLUSIONS: In the current prospective observational study, implantation of the OPTIMAX stent demonstrated an adequate 12-month clinical outcome, with a low rate of major adverse cardiac events, and no stent thrombosis.
No takes yet. Share an insight, caveat, or question.
Karjalainen et al. (2015) conducted an observational in de novo coronary lesions (n=224). OPTIMAX stent (titanium-nitride-oxide-coated cobalt-chromium stent) was evaluated on Major adverse cardiac events at 12-month follow-up (composite of cardiac death, non-fatal MI, or ischemia-driven TLR). Implantation of the OPTIMAX stent in de novo coronary lesions resulted in a 6.3% rate of major adverse cardiac events at 12 months, with no definite stent thrombosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: